U.S. Markets closed

Nivalis Therapeutics, Inc. (NVLS)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
2.35-0.04 (-1.67%)
At close: 4:00PM EDT
People also watch
Full screen
Previous Close2.39
Bid2.20 x 1500
Ask2.75 x 400
Day's Range2.30 - 2.41
52 Week Range2.00 - 9.35
Avg. Volume78,209
Market Cap36.79M
PE Ratio (TTM)-1.12
EPS (TTM)-2.09
Earnings DateJul 31, 2017 - Aug 4, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Associated Press19 hours ago

    Nivalis Therapeutics reports 2Q loss

    On a per-share basis, the Boulder, Colorado-based company said it had a loss of 24 cents. Losses, adjusted for restructuring costs, were 18 cents per share. The results exceeded Wall Street expectations. ...

  • Is a Beat in the Cards for ImmunoGen (IMGN) in Q2 Earnings?

    Is a Beat in the Cards for ImmunoGen (IMGN) in Q2 Earnings?

    ImmunoGen has made significant progress with its ovarian cancer pipeline candidate. Let's see if the company can come up with a beat this earnings season.

  • Business Wire2 days ago

    Nivalis Therapeutics Announces Results of Special Meeting of Stockholders

    Nivalis Therapeutics, Inc. announced today that, based upon the final vote count certified by the independent inspector of elections for the special meeting of stockholders held July 19, 2017, its stockholders approved all of the merger-related proposals, including:  the Agreement and Plan of Merger and Reorganization, dated as of April 18, 2017, by and among Nivalis, Nautilus Merger Sub, Inc.